Japan’s Peptide Door Receives ¥750 Million Investment From Tohoku Innovation Capital
This article was originally published in PharmAsia News
Executive Summary
Sentai, Japan-based Tohoku Innovation Capital has invested ¥750 million in Peptide Door Co., a biopharmaceutical venture company based in Takasaki, Japan, with core technology related to therapeutic peptides. Peptides allow the creation of peptide antibodies in animals without the need to purify the protein of interest, and it has received increasing attention from drug developers. Peptide Door currently is conducting joint research on a treatment for septicemia with other pharmaceutical companies. (Click here for more - Japanese language